# China Pharmaceutical University **Type:** Institutions **Canonical URL:** https://picoportal.org/library/institutions/china-pharmaceutical-university/ ## Facts | Field | Value | | --- | --- | | Avg h-index | 56.5 | | Citations | 3,638,220 | | City | Nanjing | | Country | CN | | Description | China Pharmaceutical University is a research organisation in Nanjing, CN. OpenAlex records 39,318 works and 3,638,220 citations for it. 14,710 researchers list it as their most recent affiliation. | | Homepage | https://www.cpu.edu.cn | | OpenAlex ID | https://openalex.org/I161716053 | | Researchers | 14,710 | | ROR ID | https://ror.org/01sfm2718 | | Type | education | | Wikidata ID | https://www.wikidata.org/wiki/Q5099853 | | Works | 39,318 | ## University papers Showing 12 of 124. - [EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update](https://picoportal.org/library/papers/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic/) - [EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update](https://picoportal.org/library/papers/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic-2/) - [EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update](https://picoportal.org/library/papers/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic-3/) - [Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer](https://picoportal.org/library/papers/randomized-phase-iii-keynote-181-study-of-pembrolizumab-versus-chemotherapy-in/) - [Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction](https://picoportal.org/library/papers/randomized-double-blind-placebo-controlled-phase-iii-trial-of-apatinib-in/) - [COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas](https://picoportal.org/library/papers/covid-19-immune-features-revealed-by-a-large-scale-single-cell-transcriptome/) - [Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)](https://picoportal.org/library/papers/guidelines-for-the-diagnosis-and-treatment-of-hepatocellular-carcinoma-2019/) - [Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial](https://picoportal.org/library/papers/regorafenib-plus-best-supportive-care-versus-placebo-plus-best-supportive-care/) - [Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma](https://picoportal.org/library/papers/effect-of-camrelizumab-vs-placebo-added-to-chemotherapy-on-survival-and/) - [Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study](https://picoportal.org/library/papers/brivanib-versus-sorafenib-as-first-line-therapy-in-patients-with-unresectable/) - [The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer](https://picoportal.org/library/papers/the-keynote-811-trial-of-dual-pd-1-and-her2-blockade-in-her2-positive-gastric/) - [Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification](https://picoportal.org/library/papers/phase-ii-open-label-single-arm-trial-of-imatinib-mesylate-in-patients-with/) ## University researchers Showing 15 of 22. - [Shukui Qin](https://picoportal.org/library/researchers/shukui-qin/) - [Hui Xiong](https://picoportal.org/library/researchers/hui-xiong/) - [Huijun Li](https://picoportal.org/library/researchers/huijun-li/) - [Ke Zen](https://picoportal.org/library/researchers/ke-zen/) - [Jingwen Chen](https://picoportal.org/library/researchers/jingwen-chen/) - [Huifeng Yao](https://picoportal.org/library/researchers/huifeng-yao/) - [Junqing Hu](https://picoportal.org/library/researchers/junqing-hu/) - [Tao Cheng](https://picoportal.org/library/researchers/tao-cheng-2/) - [Zhanguo Li](https://picoportal.org/library/researchers/zhanguo-li/) - [Guangji Wang](https://picoportal.org/library/researchers/guangji-wang/) - [Yehuda G. Assaraf](https://picoportal.org/library/researchers/yehuda-g-assaraf/) - [W.-M. Yao](https://picoportal.org/library/researchers/w-m-yao/) - [Wenpei Fan](https://picoportal.org/library/researchers/wenpei-fan/) - [Shukui Qin](https://picoportal.org/library/researchers/shukui-qin-2/) - [Na Lu](https://picoportal.org/library/researchers/na-lu/) ## University top topics Showing 8 of 25. - [Natural product bioactivities and synthesis](https://picoportal.org/library/topics/natural-product-bioactivities-and-synthesis/) - [Traditional Chinese Medicine Analysis](https://picoportal.org/library/topics/traditional-chinese-medicine-analysis-2/) - [Nanoplatforms for cancer theranostics](https://picoportal.org/library/topics/nanoplatforms-for-cancer-theranostics/) - [Nanoparticle-Based Drug Delivery](https://picoportal.org/library/topics/nanoparticle-based-drug-delivery/) - [Pharmacological Effects of Natural Compounds](https://picoportal.org/library/topics/pharmacological-effects-of-natural-compounds/) - [Phytochemistry and Biological Activities](https://picoportal.org/library/topics/phytochemistry-and-biological-activities/) - [Advanced biosensing and bioanalysis techniques](https://picoportal.org/library/topics/advanced-biosensing-and-bioanalysis-techniques/) - [RNA Interference and Gene Delivery](https://picoportal.org/library/topics/rna-interference-and-gene-delivery/) --- Source: PICO Portal — public research metadata, principally OpenAlex. See https://picoportal.org/library/sources/ for provenance and https://picoportal.org/library/methodology/ for what these figures mean.